Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Cipla Launches Shanghai CP Guojian’s Biosimilar in India

publication date: Apr 18, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cipla Ltd., an Indian generic drug company, has begun marketing a biosimilar version of the rheumatoid arthritis treatment Enbrel, which it sources from Shanghai CP Guojian Pharmaceutical Co. CPGJ has been selling the drug in China since 2006, where it has been given to more than 50,000 patients. Cipla described its relationship with CPGJ as a “partnership.” More details....

Stock Symbol: (BSE: 500087)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners